Composition for preventing or treating magnesium ammonium phosphate calculi of pets and application thereof

Abstract

The invention provides a composition for preventing or treating pet magnesium ammonium phosphate calculus and application thereof. The composition comprises a urine acidifying agent, a calculus formation inhibitor and a urinary tract repairing agent, the urine acidifying agent comprises any one or a combination of at least two of vitamin C, phosphate or methionine; the calculus formation inhibitor comprises a seaweed extract or / and chitosan oligosaccharide; the urinary tract repairing agent comprises any one or a combination of at least two of curcumin, hyaluronic acid, N-acetylglucosamine or cranberry extract. The composition provided by the invention synergistically maintains the pH value of pet urine to be weakly acidic, inhibits the generation of alkaline calculi, dissolves the formed alkaline calculi, repairs and protects urinary tract mucous membranes, realizes the nursing of the pet urinary system, and improves the health of the urinary system.

Description

Technical Field

[0001] This invention belongs to the field of pet stone technology, specifically relating to a composition for the prevention or treatment of pet magnesium ammonium phosphate stones and its application. Background Technology

[0002] Urolithiasis forms when mineral salts (phosphates, carbonates, calcium oxalate, urate, etc.) and protective colloidal substances (mucin, cystine, nucleic acids, mucopolysaccharides, etc.) surround mucus, blood clots, desquamated epithelial cells, necrotic tissue fragments, or foreign bodies in the bladder or renal pelvis. This severely irritates and damages the urinary tract mucosa, causing obstruction of the ureter or urinary tract. Urolithiasis is a common urinary system disease in pets. When pets drink too little water, they cannot meet their body's hydration needs. High salt content in water and food leads to an increase in precipitates over time, causing urinary tract inflammation. Urinary tract inflammation can cause tissue necrosis, and inflammatory exudates and bacterial accumulation form the core of the stone, surrounded by mineral salts and colloidal substances to solidify and form a stone.

[0003] CN113940388A discloses an additive for improving urinary tract stones in pets. This additive uses urinary tract health-promoting functional substances such as burdock seed, medium-chain fatty acids, citric acid, and lactic acid to create an additive with anti-inflammatory and diuretic properties. It lowers urine pH to promote the dissolution of canine and bird droppings and reduces the formation of canine and calcium oxalate stones. This additive can be added to pet food in a functional package, and only 1-2% needs to be added to the pet's daily diet to significantly improve and prevent canine and calcium oxalate stones.

[0004] CN117462598A discloses an enteric-coated granule for treating urinary stones in pets. The specific composition of the enteric-coated granule includes Lysimachia christinae, Plantago asiatica, Akebia quinata, Cynanchum paniculatum, Pyrrosia lingua, Lonicera japonica, Talcum, Dianthus superbus, Abutilon theophrasti, and Glycyrrhiza uralensis, and the enteric-coated granules are prepared using an enteric coating process. This product is effective in treating urinary stones in pets, especially those caused by calcium oxalate crystals, and can also reduce the risk of urinary tract inflammation caused by bacterial urinary stones, particularly struvite.

[0005] However, the formation mechanisms and inducing factors of acid urinary stones and magnesium ammonium phosphate stones in pets are significantly different, and existing products often cannot provide targeted improvement or treatment. There is an urgent need to develop a product that can prevent or treat magnesium ammonium phosphate stones in pets. Summary of the Invention

[0006] In view of the shortcomings of the prior art, the purpose of this invention is to provide a composition for the prevention or treatment of pet magnesium ammonium phosphate stones and its application. The composition of this invention can inhibit the formation of alkaline urinary stones in pets, repair and protect the urinary tract mucosa, and improve the health of the pet's urinary system.

[0007] To achieve this objective, the present invention adopts the following technical solution:

[0008] In a first aspect, the present invention provides a composition for the prevention or treatment of magnesium ammonium phosphate stones in pets, the composition comprising a urine acidifier, a stone formation inhibitor, and a urinary tract repair agent;

[0009] The urine acidifier includes any one or a combination of at least two of vitamin C, phosphate, or methionine.

[0010] The stone formation inhibitors include seaweed extracts and / or chitosan oligosaccharides;

[0011] The urinary tract repair agent includes any one or a combination of at least two of curcumin, hyaluronic acid, N-acetylglucosamine, or cranberry extract.

[0012] The composition provided by this invention synergistically maintains the pH of pet urine at a slightly acidic level, inhibits the formation of alkaline stones, dissolves existing alkaline stones, repairs and protects the urinary tract mucosa, thereby achieving care for the pet's urinary system and improving urinary system health.

[0013] The composition provided by this invention can be used daily to prevent the formation of urinary stones in pets, and can also prevent the recurrence of stones after they have already formed. The dosage is 0.05-3g of the composition orally per 5kg of body weight per day.

[0014] Preferably, the composition comprises, by weight, 5-30 parts of a urine acidifier, 5-20 parts of a stone formation inhibitor, and 1-10 parts of a urinary tract repair agent.

[0015] The urine acidifying agent can be present in parts by weight of 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 25, or 30 parts, etc.

[0016] The weight percentages of the stone formation inhibitor can be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 parts, etc.

[0017] The urinary tract repair agent can be present in parts by weight of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0018] Other specific point values ​​within the range of the above values ​​can be selected, and will not be elaborated on here.

[0019] Preferably, the urine acidifier includes vitamin C, phosphate, and methionine.

[0020] Vitamin C can protect pet urinary tract mucosal cells from oxidative damage and acidify urine; phosphates can buffer and maintain stable acidification; methionine can be metabolized into bisulfate, which directly acidifies urine and dissolves magnesium ammonium phosphate stones.

[0021] In this invention, vitamin C, phosphate and methionine have a synergistic effect. The combination of the three can stabilize urine at a slightly acidic level and inhibit the formation of alkaline urinary stones in pets.

[0022] Preferably, the mass ratio of vitamin C, phosphate and methionine is (0.5-1.5):(1-3):(20-50).

[0023] The specific point values ​​in (0.5-1.5) can be 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4 or 1.5, etc.

[0024] The specific point values ​​in (1-3) can be 1, 1.2, 1.5, 1.7, 2, 2.3, 2.5, 2.8 or 3, etc.

[0025] The specific point values ​​in (20-50) can be 20, 22, 25, 27, 30, 33, 35, 38, 40, 45 or 50, etc.

[0026] Other specific point values ​​within the range of the above values ​​can be selected, and will not be elaborated on here.

[0027] Preferably, the phosphate includes any one or a combination of at least two of sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, or dipotassium hydrogen phosphate.

[0028] Preferably, the phosphate comprises sodium dihydrogen phosphate and / or potassium dihydrogen phosphate.

[0029] Sodium dihydrogen phosphate and potassium dihydrogen phosphate produce dihydrogen phosphate ions, which can better help buffer and maintain stable acidification.

[0030] Preferably, the stone formation inhibitor includes seaweed extract and chitosan oligosaccharide.

[0031] Seaweed extract can bind magnesium ions in urine, inhibiting the nucleation and aggregation of crystals; chitosan oligosaccharide can inhibit urea-decomposing bacteria, reduce ammonia production, stabilize urine pH, and at the same time, prevent crystals from adhering to the urinary tract mucosa, reducing the inflammatory response of the urinary tract mucosa.

[0032] In this invention, seaweed extract and chitosan oligosaccharide have a synergistic effect. The combination of the three can bind magnesium ions in urine, reduce the concentration of free magnesium, inhibit crystal nucleation, and reduce the risk of microcrystals adhering to the bladder wall and urinary tract infections.

[0033] Preferably, the mass ratio of the seaweed extract to chitosan oligosaccharide is 1:(6-40).

[0034] The specific point values ​​in (6-40) can be 6, 7, 8, 9, 10, 15, 20, 25, 30, 35 or 40, etc.

[0035] Other specific point values ​​within the range of the above values ​​can be selected, and will not be elaborated on here.

[0036] Preferably, the urinary tract repair agent includes curcumin, hyaluronic acid, N-acetylglucosamine, and cranberry extract.

[0037] Curcumin has anti-inflammatory and antioxidant effects, which can reduce acute damage to the urethral mucosa and reduce inflammatory interference; N-acetylglucosamine is a precursor for the synthesis of mucosal matrix components such as hyaluronic acid and chondroitin sulfate. Hyaluronic acid can repair the structure of the urinary tract mucosa and form a protective barrier; Cranberry extract can prevent bacteria from adhering to the surface of the urinary tract mucosa, prevent bacterial infection, and protect the urinary system.

[0038] In this invention, curcumin, hyaluronic acid, N-acetylglucosamine, and cranberry extract have a synergistic effect. The combination of the four can repair urethral mucosal damage caused by crystal precipitation in urine, reduce the production of inflammatory substances, and protect the urinary system from bacterial adhesion.

[0039] Preferably, the mass ratio of curcumin, hyaluronic acid, N-acetylglucosamine and cranberry extract is (0.5-1.5):(1-3):(3-5):(3-5).

[0040] The specific point values ​​in (0.5-1.5) can be 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4 or 1.5, etc.

[0041] The specific point values ​​in (1-3) can be 1, 1.2, 1.5, 1.7, 2, 2.3, 2.5, 2.8 or 3, etc.

[0042] The specific point values ​​in (3-5) can be 3, 3.2, 3.5, 3.7, 4, 4.3, 4.5, 4.8 or 5, etc.

[0043] The specific point values ​​in (3-5) can be 3, 3.2, 3.5, 3.7, 4, 4.3, 4.5, 4.8 or 5, etc.

[0044] Other specific point values ​​within the range of the above values ​​can be selected, and will not be elaborated on here.

[0045] Preferably, the seaweed extract or cranberry extract is prepared by a method comprising the following steps: mixing plant materials and extraction reagents, ultrasonic extraction, solid-liquid separation, collecting the liquid, and obtaining the extract; wherein the plant materials include seaweed or cranberry.

[0046] The preparation of seaweed extracts or cranberry extracts involved in this invention includes, but is not limited to, the methods described above. Commonly used extract preparation methods in the field are applicable to this invention.

[0047] Preferably, the mass ratio of the plant material to the extraction reagent is 1:(5-15).

[0048] The specific point values ​​in (5-15) can be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, etc.

[0049] Other specific point values ​​within the range of the above values ​​can be selected, and will not be elaborated on here.

[0050] Preferably, the extraction reagent comprises a polyol and water.

[0051] Preferably, the polyol comprises any one or a combination of at least two of glycerol, 1,3-propanediol, 1,2-hexanediol, 1,2-pentanediol, 1,3-butanediol, ethanol, or methanol.

[0052] Preferably, the volume percentage of the polyol in the extraction reagent is 10-70%, for example, it can be 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60% or 70%, etc.

[0053] Preferably, the power of the ultrasonic extraction is 100-500W, for example, 100W, 120W, 150W, 170W, 200W, 230W, 250W, 280W, 300W, 350W, 400W, 450W, or 500W; and the time is 10-60min, for example, 10min, 15min, 20min, 25min, 30min, 35min, 40min, 45min, 50min, 55min, or 60min.

[0054] Other specific point values ​​within the range of the above values ​​can be selected, and will not be elaborated on here.

[0055] Preferably, the collected liquid further includes a concentration and drying step.

[0056] Preferably, the composition further includes a functionalizing agent.

[0057] Preferably, the composition further comprises 40-89 parts by weight of a functionalizing agent.

[0058] The functionalizing agent can be present in weight parts of 40, 42, 45, 47, 50, 53, 55, 58, 60, 70, 80, or 89 parts, etc.

[0059] Other specific point values ​​within the range of the above values ​​can be selected, and will not be elaborated on here.

[0060] Preferably, the functionalizing agent includes any one or a combination of at least two of amino acids, vitamins, probiotics, animal meat products, or plant dietary fiber.

[0061] In a second aspect, the present invention provides the use of the composition as described in the first aspect in the preparation of a medicament for the prevention or treatment of pet magnesium ammonium phosphate stones.

[0062] Thirdly, the present invention provides the use of the composition as described in the first aspect in the preparation of pet food for preventing pet magnesium ammonium phosphate stones.

[0063] Preferably, the composition has a mass percentage content of 0.1-10% in the pet food, for example, it can be 0.1%, 0.2%, 0.5%, 1%, 1.3%, 1.5%, 1.8%, 2%, 5%, 7% or 10%, etc.

[0064] Other specific point values ​​within the range of the above values ​​can be selected, and will not be elaborated on here.

[0065] Compared with the prior art, the present invention has the following beneficial effects:

[0066] The composition provided by this invention synergistically maintains the pH of pet urine at a slightly acidic level, inhibits the formation of alkaline stones, dissolves existing alkaline stones, repairs and protects the urinary tract mucosa, thereby achieving care for the pet's urinary system and improving urinary system health. Detailed Implementation

[0067] To further illustrate the technical means and effects of the present invention, the following describes the technical solution of the present invention in conjunction with preferred embodiments of the present invention. However, the present invention is not limited to the scope of the embodiments.

[0068] Where specific techniques or conditions are not specified in the examples, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.

[0069] The sources of materials used in the following specific embodiments are as follows:

[0070] Chitosan oligosaccharide was purchased from Shandong Guanghao Biological Products Co., Ltd.; hyaluronic acid was purchased from Shandong Liyang Biotechnology Co., Ltd.

[0071] Preparation Example 1

[0072] This preparation example provides a seaweed extract, which is prepared by a method comprising the following steps:

[0073] The seaweed was washed, dried, crushed, and sieved. It was then mixed with a 40 vol% methanol aqueous solution at a mass ratio of 1:10 and ultrasonically extracted for 30 minutes at a power of 300W. The mixture was filtered, the liquid was collected, concentrated, and dried to obtain the seaweed extract.

[0074] Preparation Example 2

[0075] This preparation example provides a seaweed extract, which is prepared by a method comprising the following steps:

[0076] The seaweed was washed, dried, crushed, and sieved. It was then mixed with a 70 vol% ethanol aqueous solution at a mass ratio of 1:5 and ultrasonically extracted for 10 min at a power of 500 W. The mixture was then filtered, the liquid was collected, concentrated, and dried to obtain the seaweed extract.

[0077] Preparation Example 3

[0078] This preparation example provides a seaweed extract, which is prepared by a method comprising the following steps:

[0079] The seaweed was washed, dried, pulverized, and sieved. It was then mixed with a 10 vol% 1,3-propanediol aqueous solution at a mass ratio of 1:15 and ultrasonically extracted for 60 minutes at 100W. The mixture was then filtered, the liquid was collected, concentrated, and dried to obtain the seaweed extract.

[0080] Preparation Example 4

[0081] This preparation example provides a cranberry extract, which differs from Preparation Example 1 only in that "seaweed" is replaced with "cranberry", while the other steps and raw materials remain unchanged.

[0082] Preparation Example 5

[0083] This preparation example provides a cranberry extract, which differs from Preparation Example 2 only in that "seaweed" is replaced with "cranberry", while the other steps and raw materials remain unchanged.

[0084] Preparation Example 6

[0085] This preparation example provides a cranberry extract, which differs from Preparation Example 3 only in that "seaweed" is replaced with "cranberry", while the other steps and raw materials remain unchanged.

[0086] Example 1

[0087] This embodiment provides a composition comprising the following components in parts by weight:

[0088]

[0089] The preparation method is simply to mix the above raw materials evenly.

[0090] Example 2

[0091] This embodiment provides a composition comprising the following components in parts by weight:

[0092]

[0093] The preparation method is simply to mix the above raw materials evenly.

[0094] Example 3

[0095] This embodiment provides a composition comprising the following components in parts by weight:

[0096]

[0097] The preparation method is simply to mix the above raw materials evenly.

[0098] Example 4

[0099] This embodiment provides a composition that differs from Example 1 only in that: vitamin C is not added to the urine acidifier, and its reduced proportion is allocated to sodium dihydrogen phosphate and DL-methionine, while the remaining raw materials and steps remain unchanged.

[0100] Example 5

[0101] This embodiment provides a composition that differs from Example 1 only in that sodium dihydrogen phosphate is not added to the urine acidifier, and its reduced proportion is allocated to vitamin C and DL-methionine, while the remaining raw materials and steps remain unchanged.

[0102] Example 6

[0103] This embodiment provides a composition that differs from Example 1 only in that DL-methionine is not added to the urine acidifier, and its reduced proportion is allocated to vitamin C and sodium dihydrogen phosphate, while the remaining raw materials and steps remain unchanged.

[0104] Example 7

[0105] This embodiment provides a composition that differs from Example 1 only in that: no seaweed extract is added to the stone formation inhibitor, and the reduced amount is made up by chitosan oligosaccharide, while the other raw materials and steps remain unchanged.

[0106] Example 8

[0107] This embodiment provides a composition that differs from Example 1 only in that: chitosan oligosaccharide is not added to the stone formation inhibitor, and its reduced amount is made up by seaweed extract, while the other raw materials and steps remain unchanged.

[0108] Example 9

[0109] This embodiment provides a composition that differs from Example 1 only in that curcumin is not added to the urinary tract repair agent, but its proportion is reduced and allocated to hyaluronic acid, N-acetylglucosamine and cranberry extract, while the other raw materials and steps remain unchanged.

[0110] Example 10

[0111] This embodiment provides a composition that differs from Example 1 only in that: hyaluronic acid is not added to the urinary tract repair agent, and its proportion is reduced and allocated to curcumin, N-acetylglucosamine and cranberry extract, while the other raw materials and steps remain unchanged.

[0112] Example 11

[0113] This embodiment provides a composition that differs from Example 1 only in that: N-acetylglucosamine is not added to the urinary tract repair agent, and its reduced proportion is allocated to curcumin, hyaluronic acid and cranberry extract, while the other raw materials and steps remain unchanged.

[0114] Example 12

[0115] This embodiment provides a composition that differs from Example 1 only in that: cranberry extract is not added to the urinary tract repair agent, but its proportion is reduced and allocated to curcumin, hyaluronic acid and N-acetylglucosamine, while the other raw materials and steps remain unchanged.

[0116] Comparative Example 1

[0117] This comparative example provides a composition that differs from Example 1 only in that: no urine acidifier is added, and its reduced proportion is allocated to the stone formation inhibitor and the urinary tract repair agent, while the other raw materials and steps remain unchanged.

[0118] Comparative Example 2

[0119] This comparative example provides a composition that differs from Example 1 only in that: no stone formation inhibitor is added, and its reduced proportion is allocated to the urine acidifier and urinary tract repair agent, while the remaining raw materials and steps remain unchanged.

[0120] Comparative Example 3

[0121] This comparative example provides a composition that differs from Example 1 only in that: no urinary tract repair agent is added, and its reduced proportion is allocated to the urine acidifier and stone formation inhibitor, while the remaining raw materials and steps remain unchanged.

[0122] Test case

[0123] Adult Chinese domestic cats, primarily orange tabby, weighing 3-6 kg, with similar weight, age, and mental state, but exhibiting slightly alkaline urine pH, were selected for the experiment. They were randomly assigned to groups and administered the compositions provided in Examples 1-12 or Comparative Examples 1-3 orally at a rate of 0.8 g per 5 kg of body weight daily for 28 days. Each group consisted of 3 cats, and there were no statistically significant differences in sex, age, or weight among the groups. All experimental cats were housed individually in separate cages at an ambient temperature of 20-25℃ and humidity of 40-60%. During the experiment, standard feeding and disinfection procedures were followed, with free access to food and water. Antibiotics and other medications were prohibited for one month prior to the experiment. During the formal experiment, the experimental cats were fed food at 8:00 AM daily, and the daily food consumption was recorded. 300 mL of clean drinking water was provided to the cats at a fixed time each day, and any remaining drinking water was collected and measured using a measuring cylinder at the same time the following day. On day 28 of the trial period, urine was collected using Danish KRUUSE non-absorbent cat litter, with a sample volume of approximately 5 mL. The pH value of the urine was measured using a Mindray UA-600T semi-automatic urine analyzer. In addition, 10 mL of urine was centrifuged at 3000 r / min for 10 min, and 0.75 mL of urine and sediment were collected. Urine crystals were observed and counted using a standard urine sediment counting chamber.

[0124] The test results are shown in Table 1. The composition provided by this invention synergistically maintains the pH of pet urine at a slightly acidic level, inhibits the formation of alkaline stones, dissolves existing alkaline stones, and improves urinary system health. Specifically, vitamin C, phosphate, and methionine have synergistic effects; seaweed extract and chitosan oligosaccharide have synergistic effects; curcumin, hyaluronic acid, N-acetylglucosamine, and cranberry extract have synergistic effects. The synergistic combination of these components regulates the pH of pet urine within a slightly acidic range, controls the formation of magnesium ammonium phosphate stones, and achieves urinary system care for pets.

[0125] Table 1

[0126]

[0127]

[0128] This invention illustrates a composition for the prevention or treatment of pet magnesium ammonium phosphate stones and its application through the above embodiments. However, this invention is not limited to the above embodiments, meaning that this invention does not necessarily rely on the above embodiments for implementation. Those skilled in the art should understand that any improvements to this invention, equivalent substitutions of the raw materials in the product of this invention, addition of auxiliary components, and selection of specific methods, etc., all fall within the protection and disclosure scope of this invention.

[0129] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the protection scope of the present invention.

[0130] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not describe the various possible combinations separately.

Claims

1. A composition for the prevention or treatment of magnesium ammonium phosphate stones in pets, characterized in that, The composition includes a urine acidifier, a stone formation inhibitor, and a urinary tract repair agent; The urine acidifier includes any one or a combination of at least two of vitamin C, phosphate, or methionine. The stone formation inhibitors include seaweed extracts and / or chitosan oligosaccharides; The urinary tract repair agent includes any one or a combination of at least two of curcumin, hyaluronic acid, N-acetylglucosamine, or cranberry extract.

2. The composition according to claim 1, characterized in that, The composition comprises, by weight, 5-30 parts of urine acidifier, 5-20 parts of stone formation inhibitor, and 1-10 parts of urinary tract repair agent.

3. The composition according to claim 1 or 2, characterized in that, The urine acidifiers include vitamin C, phosphates, and methionine; Preferably, the mass ratio of vitamin C, phosphate and methionine is (0.5-1.5):(1-3):(20-50); Preferably, the phosphate includes any one or a combination of at least two of sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, or dipotassium hydrogen phosphate.

4. The composition according to any one of claims 1-3, characterized in that, The stone formation inhibitors include seaweed extract and chitosan oligosaccharide; Preferably, the mass ratio of the seaweed extract to chitosan oligosaccharide is 1:(6-40).

5. The composition according to any one of claims 1-4, characterized in that, The urinary tract repair agent includes curcumin, hyaluronic acid, N-acetylglucosamine, and cranberry extract; Preferably, the mass ratio of curcumin, hyaluronic acid, N-acetylglucosamine and cranberry extract is (0.5-1.5):(1-3):(3-5):(3-5).

6. The composition according to any one of claims 1-5, characterized in that, The composition also includes a functionalizing agent; Preferably, the composition further comprises 40-89 parts by weight of a functionalizing agent.

7. The composition according to claim 6, characterized in that, The functionalizing agent includes any one or a combination of at least two of the following: amino acids, vitamins, probiotics, animal meat products, or plant dietary fiber.

8. Use of the composition according to any one of claims 1-7 in the preparation of a medicament for the prevention or treatment of pet magnesium ammonium phosphate stones.

9. The use of the composition according to any one of claims 1-7 in the preparation of pet food for preventing pet magnesium ammonium phosphate stones.

10. The application according to claim 9, characterized in that, The composition is present in pet food at a mass percentage of 0.1-10%.

Images